Vizsgálati helyszín
London Digestive Disease Institute
London, N6K 1M6, KanadaMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis8 vizsgálat
- 3. fázis6 vizsgálat
- 4. fázis2 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz11 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Még nem toboroz3 vizsgálat
- Fő szponzor
- Eli Lilly and Company7 vizsgálat
- Janssen Research & Development, LLC5 vizsgálat
- Alimentiv Inc.1 vizsgálat
- Genentech, Inc.1 vizsgálat
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 vizsgálat
- és még 2
Futó vizsgálatok
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· 2. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099· 2. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
NCT06997965· 4. fázis· Alimentiv Inc.· Forrás
Contact: Jennifer Earle
Toboroz
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· 2. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· 2. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· 2. fázis· Genentech, Inc.· Forrás
Toboroz
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· 3. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· 3. fázis· Eli Lilly and Company· Forrás
Contact: Vipul Jairath (principal investigator)
Fut, nem toboroz
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Contact: Vipul Jairath (principal investigator)
Toboroz
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039· 4. fázis· University of Calgary· Forrás
Contact: Vipul Jairath
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek